Philip Rutten

I’m a postdoc under the supervision of Wessel van Wieringen and Costa Bachas.

My research focuses on the development of computational methods for the automated analysis of flow cytometry assays from patients at different therapeutic time points. Flow cytometry data consist of multi-parameter measurements of protein expressions of up to millions of cells per sample. We aim to develop prediction models based on the automated assessment of minimal residual disease (MRD) after chemotherapy in acute myeloid leukemia (AML) patients. MRD is a powerful predictor for treatment outcome and the evaluation of risk of relapse. Our efforts are directed at estimating leukaemic cell proportions using statistical mixture models for clustering and cell population classification.

The research project is a collaboration between the Hematology Laboratories in the Cancer Center Amsterdam and the Department of Epidemiology and Data Science of Amsterdam UMC.